Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review.

ABSTRACT: Insomnia is a common, impairing, and difficult-to-treat comorbidity in children with neurodevelopmental disorders (NDDs). Behavioral interventions can be challenging because of developmental and behavioral features that interfere with treatment. Medication management also can be difficult due to a high burden of side effects, a high rate of paradoxical responses, and frequent treatment resistance. Therefore, new treatment options for insomnia in children with NDDs are needed. Dual orexin receptor antagonists (DORAs) are a relatively new class of pharmacotherapeutics that induce sleep by inhibiting the orexin signaling pathway. To date, there is little safety or efficacy data on the use of DORAs in children with NDDs. We present four patients with NDDs and insomnia that we treated with the

SUBMITTER: Besterman AD 

PROVIDER: S-EPMC10038945 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature